Loading...
  • combination
  • The results in the present study showed that 60 mg m -2 of Epirubicin given as a constant rate infusion over 2 hours is a useful alternative to more aggressive combination drug therapy for the treatment of breast cancer. (springer.com)
  • The epirubicin/docetaxel combination is one of the most active and best tolerated taxane/anthracycline combinations. (bioportfolio.com)
  • adverse events
  • 3. Use of chemotherapeutic agents for any malignancy within 4 weeks prior to study entry or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. (knowcancer.com)
  • therapy
  • range 36-78 years) were treated with Epirubicin (4'epi-Dox-orubicin), 60 mg m -2 , as single drug therapy. (springer.com)
  • The homologous recombination deficiency (HRD) score may be a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple-negative breast cancer, according to studies presented at the 2015 San Antonio Breast Cancer Symposium. (ascopost.com)
  • It is now possible to provide therapy at a molecular level with the help of these tools, thus treating the disease and assisting in study of the pathogenesis of disease. (biomedsearch.com)
  • breast
  • Dixon A R, Robertson J F R, Athanassiou E, Jackson L, Blarney R W: Weekly Low Dosage Epirubicin in Advanced Breast Cancer. (springer.com)
  • In screening for breast cancer, results from a study in the United Kingdom suggest that the use of "synthetic" two-dimensional (2D) mammography, rather than 2D/three-dimensional (3D) combinations, could save radiologists' time and patients' exposure to radiation as well as result in many fewer. (ascopost.com)
  • Studies presented at the 2015 San Antonio Breast Cancer Symposium built upon an increasing body of data in support of the neoadjuvant use of carboplatin in patients with triple-negative breast cancer. (ascopost.com)
  • Lactation Outcomes in More Than 3500 Women Following Primary Augmentation: 5-Year Data From the Breast Implant Follow-Up Study. (bioportfolio.com)
  • The Breast Implant Follow-up Study (BIFS-001) is a large, 10-year observational study evaluating the perfor. (bioportfolio.com)
  • Purpose Randomized, controlled trials showed that screening reduces breast cancer mortality rates, but some recent observational studies have concluded that programmatic screening has had minor effect. (bioportfolio.com)
  • Years
  • 1. Previous malignancies, excluding curatively treated basal or squamous cell carcinoma of the skin or in-situ cervical cancer or any other cancer treated more than five years prior to study entry and presumed cured. (knowcancer.com)
  • In a study of 1,713 diverse childhood cancer survivors, 48% to 65% displayed impaired pulmonary functions, hearing loss, endocrine dysfunction, cardiac disorders, and neurocognitive impairments at a median of 25 years after diagnosis ( 7-9 ). (aacrjournals.org)
  • Sixty-seven patients aged 52.58 ± 13.86 years with large B-cell non-Hodgkin lymphoma treated with epirubicin were studied. (biomedsearch.com)
  • clinical study
  • A work that reports on the results of a clinical study in which participants may receive diagnostic, therapeutic, or other types of interventions, but the investigator does not assign participants to specific interventions (as in an interventional study). (bioportfolio.com)
  • participation
  • Leucocytes limits (1,25 above upper normal limit), Creatinine-Clearance below 50 ml/min, uncompensated cardiac function, severe and relevant co-morbidity that would interact with the application of cytotoxic agents or the participation in the study. (knowcancer.com)